الفهرس 
INTRINSIC IMMUNE PROCESS AGAINST CANCEROnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
The aim of this work was to determine the objective response, efficacy and feasibility of immunologic effects of autologous immune enhancement against advanced solid tumours. The present study included 24 patients with pathologically proven advanced solid cancers were stratified in two groups according to performance status and primary diagnosis. All of the patients had advanced disease and were previously treated with standard chemotherapy and or radiotherapy.
Baseline assessments were done prior to the treatment for evaluation of the initial disease and these assessments were repeated after 8-12 weeks of treatment and comparison using RECIST criteria.
Peripheral blood was used as source of tumour antigen which stimulated immune response after being injected subcutaneously. After the immune enhancement procedure, there were delayed immune response noted in patients with favourable response as demonstrated by delayed hyper-sensitivity reaction.
Toxicity recorded in this study was limited and only grade-1 toxicity was recorded in the treatment group with insignificant P value in comparison between the two groups. No major morbidities or mortalities were recorded during the follow up period.
Overall results of this series demonstrated the technique is safe and feasible. The results support the theory that peripheral blood can be used as a source of tumour antigen although it did not shown clinical response as evaluated by using RECIST criteria for advanced stages of solid tumours.
Sustainability of the favourable response was limited as all patients with initial partial response had disease progression within 6 month period. This research had limitations due to the heterogeneity of the patient population and small number of cases. However, the results indicate the following innovative findings that merit further research in a trial of more advanced design.